Enzyme Kinetics and Inhibition

Michaelis-Menten Kinetics (Normal Enzyme Function)

• Vmax (maximum velocity) represents the catalytic capacity when enzyme is fully saturated with substrate; limited by [E]total and kcat (turnover number)
• Km (Michaelis constant) reflects substrate affinity and enzyme-substrate complex stability; lower Km = higher affinity; independent of enzyme concentration
• Vmax = (kcat × [E]total × [S]) / (Km + [S]) at steady state; at [S] = Km, velocity = 0.5 × Vmax
• Enzymes follow zero-order kinetics at high substrate (V ≈ Vmax, all enzyme saturated) and first-order kinetics at low substrate (V proportional to [S])

Competitive Inhibition

• Inhibitor competes with substrate for the active site; reversible or irreversible binding
• Increases apparent Km (higher substrate needed for same velocity) while Vmax remains unchanged
• Can be overcome by increasing substrate concentration; classic example: statins competing with HMG-CoA for HMG-CoA reductase
• Reversible competitive inhibitors follow V = (Vmax × [S]) / (Km(1 + [I]/Ki) + [S])

Non-Competitive Inhibition

• Inhibitor binds to allosteric site or enzyme-substrate complex; does NOT compete with substrate
• Decreases Vmax while Km remains unchanged; cannot be overcome by increasing substrate
• Results in parallel shift of Lineweaver-Burk plot; example: heavy metal inhibition of metalloproteins

Mixed Inhibition

• Inhibitor binds to both free enzyme and enzyme-substrate complex with different affinities
• Both Vmax and Km are affected (Km may increase or decrease depending on relative binding affinities)
• Reflects complex allosteric regulation; seen with covalent modification inhibitors

Irreversible Inhibition

• Covalent modification of active site (e.g., acetylation by aspirin of COX-1 serine, phosphorylation of kinases)
• Cannot be overcome by competitor or dilution; requires new enzyme synthesis for activity restoration
• Often suicide inhibitors (mechanism-based): substrate analog that generates reactive intermediate binding covalently

Enzyme Regulation Mechanisms

• Allosteric regulation: regulatory molecules bind distant sites, changing Km or Vmax without active-site competition
• Covalent modification: phosphorylation (reversible), methylation, ubiquitination (affects activity or localization)
• Cofactor/coenzyme availability: NAD+/NADH ratios, metal ions (Zn2+, Mg2+), biotin, heme
• Feedback inhibition: end product inhibits pathway-initiating enzyme (e.g., CTP inhibits aspartate transcarbamoylase)
• Compartmentalization: substrate and enzyme separation prevents reactions
• Proenzyme activation: inactive zymogens (digestive enzymes, caspases, complement) activated by proteolytic cleavage or cascade

Effects of Enzyme Inhibition (Variable by Target Enzyme)

• Metabolic accumulation: substrate buildup proximal to inhibited enzyme causes pathology (e.g., phenylketonuria from PAH deficiency → elevated phenylalanine → neurological damage if untreated)
• Product deficiency: loss of downstream metabolite causes disease (e.g., allopurinol inhibits xanthine oxidase → reduced uric acid production and gout prevention, but increased xanthine can crystallize in rare cases)
• Drug toxicity presentations: variable based on target enzyme; competitive inhibitors present as dose-dependent effects while irreversible inhibitors show delayed or cumulative toxicity

Classic Clinical Presentations by Enzyme Class

• Protease inhibitors (HIV protease, ACE): reduced substrate cleavage causes accumulation of inactive precursors or loss of active peptides
• Kinase inhibitors: blocked phosphorylation prevents signal transduction (therapeutic in cancer; side effects from off-target inhibition)
• Monoamine oxidase inhibitors (MAOIs): reduced catecholamine/serotonin degradation → hypertensive crisis with sympathomimetics, serotonin syndrome with SSRIs
• Cytochrome P450 inhibition (ketoconazole, erythromycin, grapefruit juice): impaired drug metabolism → elevated drug levels, toxicity, QT prolongation

Patient Risk Factors for Inhibitor Toxicity

• Polypharmacy (drug-drug interactions at CYP450 level)
• Hepatic/renal impairment (reduced inhibitor clearance; altered target enzyme expression)
• Genetic polymorphisms (CYP2D6 poor metabolizers at higher risk from P450 inhibitors)
• Advanced age (reduced hepatic metabolism, altered pharmacokinetics)

Laboratory Assessment of Enzyme Activity

• Direct enzyme assay: measure reaction rate under standardized conditions (substrate, cofactors, pH, temperature); calculate Vmax and Km from substrate titration curves
• Lineweaver-Burk plot (1/V vs. 1/[S]): linearizes Michaelis-Menten equation for visual identification of inhibition type; y-intercept = 1/Vmax, x-intercept = -1/Km
• Eadie-Hofstee plot (V vs. V/[S]): alternative linear transformation; helpful for distinguishing inhibition types
• Double reciprocal analysis: competitive inhibition shows intersecting lines (same y-intercept, different x-intercepts); non-competitive shows parallel lines

Clinical Diagnostic Indicators of Enzyme Inhibition

• Substrate accumulation: elevated levels of substrate proximal to blocked step (uric acid in allopurinol use, phenylalanine in PKU)
• Product deficiency: low levels of expected enzyme product (reduced dopamine with MAOIs causing apathy/depression; reduced serotonin initially)
• Pharmacokinetic studies: elevated parent drug or reduced metabolite levels indicating CYP inhibition (check drug levels: digoxin, theophylline, warfarin when co-prescribed with P450 inhibitors)
• Genetic testing: CYP450 polymorphisms (CYP2D6, CYP2C19) predict poor/rapid metabolism and inhibitor sensitivity

Important Diagnostic Pearls

• Ki (inhibition constant) quantifies inhibitor potency; lower Ki = tighter binding = greater inhibition; compare Ki to substrate Km to predict clinical significance
• IC50 (concentration causing 50% inhibition) used in drug screening; distinguishing between IC50 and Ki helps predict dose-response
• Time course of inhibition effect distinguishes reversible (rapid offset) from irreversible inhibition (prolonged effect despite drug clearance)

Management Depends on Inhibition Type and Clinical Context

Competitive Inhibition Management

• Increase substrate concentration if physiologically feasible (e.g., increasing dietary phenylalanine may overcome mild PAH inhibition, though not applicable to most clinical scenarios)
• Reduce inhibitor dose or substitute alternative drug without competitive mechanism
• Monitor for reduced efficacy of co-administered substrates (e.g., reduced antibiotic efficacy if P450 induction occurs via competitor metabolism)
• Time-separate dosing of competitive drugs when possible (space acetaminophen and warfarin dosing to minimize interaction)

Non-Competitive Inhibition Management

The four kinetic patterns (highest-yield single fact set)

• Competitive: apparent Km increases, Vmax unchanged — inhibitor and substrate compete for the active site, so more substrate wins. On the Lineweaver-Burk plot, lines share the y-intercept (1/Vmax) and the x-intercept moves toward zero.
• Noncompetitive (pure): Vmax decreases, Km unchanged — shared x-intercept, different y-intercepts; extra substrate cannot rescue activity.
• Uncompetitive: inhibitor binds only the ES complex, so both Vmax and Km decrease (lines are parallel). This is the most common distractor when a stem says "both parameters fell" — do not reflexively call it noncompetitive.
• Irreversible/suicide: kinetically mimics noncompetitive (falling Vmax) but effect outlasts drug clearance and requires new enzyme synthesis — aspirin on COX-1, PPIs on H+/K+-ATPase, MAOI-B inhibitors.

Parameter traps examiners reuse

• Km is an affinity term, not a capacity term: low Km = high affinity; Km is independent of enzyme concentration, while Vmax is directly proportional to [E]total. Doubling enzyme doubles Vmax and leaves Km untouched.
• Potency vs efficacy: a competitive inhibitor shifts a dose-response curve right (decreased potency, same maximal effect); a noncompetitive inhibitor lowers the maximum (decreased efficacy).
• Hexokinase vs glucokinase is the classic Km/Vmax pairing: hexokinase has low Km/low Vmax (works at low glucose, ubiquitous), hepatic glucokinase has high Km/high Vmax and is induced by insulin — the glucose sensor.
• Sigmoidal (S-shaped) curve = cooperativity, not Michaelis-Menten; think hemoglobin O2 binding and aspartate transcarbamoylase feedback-inhibited by CTP.

Clinical single-best-next-step items

• Toxic alcohol ingestion (methanol, ethylene glycol) is the board's competitive-inhibition vignette: fomepizole, an alcohol dehydrogenase inhibitor, is the US first-line antidote, plus hemodialysis for severe acidosis or visual loss.
• Statins (HMG-CoA reductase inhibitors) are the prototype therapeutic competitive inhibitor and remain first-line LDL-lowering therapy under the ACC/AHA 2018 Multisociety Cholesterol Guideline.
• Zero-order (saturable) elimination — phenytoin, ethanol, high-dose aspirin — means small dose increases cause disproportionate toxicity; check a level rather than assuming linear kinetics.